tiprankstipranks
Lineage Cell Therapeutics, Inc. (IL:LCTX)
TASE:LCTX
Israel Market
LCTX
Lineage Therap
RESEARCH TOOLSreports

Lineage Therap (LCTX) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

LCTX Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Lineage
Therap
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LCTX Stock 12 Month Forecast

Average Price Target

2,108.27
▲(557.19% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Lineage Therap in the last 3 months. The average price target is 2,108.27 with a high forecast of 2,710.64 and a low forecast of 903.55. The average price target represents a 557.19% change from the last price of 320.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"354":"354","2711":"2,711","943.25":"943.3","1532.5":"1,532.5","2121.75":"2,121.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2710.63926,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.71K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2108.27498,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":903.54642,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">903.55</span>\n  </div></div>","useHTML":true}}],"tickPositions":[354,943.25,1532.5,2121.75,2711],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,364.4,544.879943076923,725.3598861538461,905.8398292307692,1086.3197723076923,1266.7997153846154,1447.2796584615385,1627.7596015384615,1808.2395446153846,1988.7194876923077,2169.1994307692307,2349.679373846154,2530.159316923077,{"y":2710.63926,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,364.4,498.54422923076925,632.6884584615384,766.8326876923077,900.9769169230769,1035.1211461538462,1169.2653753846153,1303.4096046153845,1437.5538338461538,1571.698063076923,1705.8422923076923,1839.9865215384616,1974.1307507692309,{"y":2108.27498,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,364.4,405.87280153846154,447.34560307692306,488.81840461538457,530.2912061538461,571.7640076923077,613.2368092307693,654.7096107692307,696.1824123076923,737.6552138461539,779.1280153846153,820.6008169230769,862.0736184615384,{"y":903.54642,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":355.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":596.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":601.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":568.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":535.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":581.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":482,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":442.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":377.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":408.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":364.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target2,711Average Price Target2,108Lowest Price Target903.55
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IL:LCTX
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
2,710.64
Buy
744.96%
Upside
Reiterated
07/14/26
Lineage Therap (LCTX) Gets a Buy from H.C. Wainwright
Craig-Hallum Analyst forecast on IL:LCTX
Albert Lowe
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
07/14/26
Analysts' Top Healthcare Picks: Lineage Therap (LCTX), Syndax Pharmaceuticals (SNDX)
Maxim Group Analyst forecast on IL:LCTX
Michael Okunewitch
Maxim Group
Maxim Group
903.55
Buy
181.65%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Lineage Therap (NYSE MKT: LCTX) and RenovoRx (NASDAQ: RNXT)
Canaccord Genuity Analyst forecast on IL:LCTX
John Newman
Canaccord Genuity
Canaccord Genuity
2,710.64
Buy
744.96%
Upside
Reiterated
05/13/26
Canaccord Genuity Reaffirms Their Buy Rating on Lineage Therap (LCTX)
B. Riley Securities Analyst forecast on IL:LCTX
Mayank Mamtani
B. Riley Securities
B. Riley Securities
903.55→1,204.73
Buy
275.54%
Upside
Reiterated
03/25/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Robert W. Baird Analyst forecast on IL:LCTX
Jack Allen
Robert W. Baird
Robert W. Baird
1,505.91
Buy
369.42%
Upside
Reiterated
09/23/25
Robert W. Baird Sticks to Its Buy Rating for Lineage Therap (LCTX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IL:LCTX
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
2,710.64
Buy
744.96%
Upside
Reiterated
07/14/26
Lineage Therap (LCTX) Gets a Buy from H.C. Wainwright
Craig-Hallum Analyst forecast on IL:LCTX
Albert Lowe
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
07/14/26
Analysts' Top Healthcare Picks: Lineage Therap (LCTX), Syndax Pharmaceuticals (SNDX)
Maxim Group Analyst forecast on IL:LCTX
Michael Okunewitch
Maxim Group
Maxim Group
903.55
Buy
181.65%
Upside
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (NASDAQ: TNYA), Lineage Therap (NYSE MKT: LCTX) and RenovoRx (NASDAQ: RNXT)
Canaccord Genuity Analyst forecast on IL:LCTX
John Newman
Canaccord Genuity
Canaccord Genuity
2,710.64
Buy
744.96%
Upside
Reiterated
05/13/26
Canaccord Genuity Reaffirms Their Buy Rating on Lineage Therap (LCTX)
B. Riley Securities Analyst forecast on IL:LCTX
Mayank Mamtani
B. Riley Securities
B. Riley Securities
903.55→1,204.73
Buy
275.54%
Upside
Reiterated
03/25/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Robert W. Baird Analyst forecast on IL:LCTX
Jack Allen
Robert W. Baird
Robert W. Baird
1,505.91
Buy
369.42%
Upside
Reiterated
09/23/25
Robert W. Baird Sticks to Its Buy Rating for Lineage Therap (LCTX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lineage Therap

3 Months
Michael OkunewitchMaxim Group
Success Rate
8/13 ratings generated profit
62%
Average Return
+32.08%
Copying Michael Okunewitch's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +32.08% per trade.
1 Year
Michael OkunewitchMaxim Group
Success Rate
8/13 ratings generated profit
62%
Average Return
+66.08%
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +66.08% per trade.
2 Years
Michael OkunewitchMaxim Group
Success Rate
9/13 ratings generated profit
69%
Average Return
+39.24%
Copying Michael Okunewitch's trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +39.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LCTX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
4
9
5
6
1
Buy
0
0
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
9
5
7
2
In the current month, LCTX has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LCTX average Analyst price target in the past 3 months is 2,108.27.
Each month's total comprises the sum of three months' worth of ratings.

LCTX Financial Forecast

LCTX Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

LCTX Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

LCTX Stock Forecast FAQ

What is IL:LCTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Lineage Cell Therapeutics, Inc.’s 12-month average price target is 2,108.27.
    What is IL:LCTX’s upside potential, based on the analysts’ average price target?
    Lineage Cell Therapeutics, Inc. has 557.19% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Lineage Cell Therapeutics, Inc. a Buy, Sell or Hold?
          Lineage Cell Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Lineage Cell Therapeutics, Inc.’s share price target?
            The average share price target for Lineage Cell Therapeutics, Inc. is 2,108.27. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 2,710.64 ,and the lowest forecast is 903.55. The average share price target represents 557.19% Increase from the current price of 320.8.
              What do analysts say about Lineage Cell Therapeutics, Inc.?
              Lineage Cell Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Lineage Cell Therapeutics, Inc.?
                To buy shares of IL:LCTX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.